Neutralizing Antibody Responses against Five SARS-CoV-2 Variants and T Lymphocyte Change after Vaccine Breakthrough Infections from the SARS-CoV-2 Omicron BA.1 Variant in Tianjin, China: A Prospective Study

被引:1
|
作者
Zhang, Ying [1 ]
Qu, Jiang Wen [1 ]
Zheng, Min Na [1 ,2 ]
Ding, Ya Xing [1 ]
Chen, Wei [1 ]
Ye, Shao Dong [3 ]
Li, Xiao Yan [1 ,2 ]
Li, Yan Kun [1 ,2 ]
Liu, Ying [1 ]
Zhu, Di [1 ,2 ]
Jin, Can Rui [4 ]
Wang, Lin [4 ]
Yang, Jin Ye [4 ]
Zhai, Yu [4 ]
Wang, Er Qiang [4 ]
Meng, Xing [4 ]
机构
[1] Tianjin Ctr Dis Control & Prevent, Tianjin 300011, Peoples R China
[2] Tianjin Key Lab Pathogen Microbiol Infect Dis, Tianjin 300011, Peoples R China
[3] Chinese Ctr Dis Control & Prevent, Natl Ctr AIDS STD Control & Prevent, Beijing 102206, Peoples R China
[4] Sinovac Biotech Ltd, Beijing 100085, Peoples R China
关键词
SARS-CoV-2; COVID-19; Omicron BA.1; T cells; Neutralizing antibodies; IMMUNITY;
D O I
10.3967/bes2023.047
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Objective To investigate whether Omicron BA.1 breakthrough infection after receiving the SARS-CoV-2 vaccine could create a strong immunity barrier.Methods Blood samples were collected at two different time points from 124 Omicron BA.1 breakthrough infected patients and 124 controls matched for age, gender, and vaccination profile. Live virus-neutralizing antibodies against five SARS-CoV-2 variants, including WT, Gamma, Beta, Delta, and Omicron BA.1, and T-lymphocyte lymphocyte counts in both groups were measured and statistically analyzed.Results The neutralizing antibody titers against five different variants of SARS-CoV-2 were significantly increased in the vaccinated population infected with the Omicron BA.1 variant at 3 months after infection, but mainly increased the antibody level against the WT strain, and the antibody against the Omicron strain was the lowest. The neutralizing antibody level decreased rapidly 6 months after infection. The T-lymphocyte cell counts of patients with mild and moderate disease recovered at 3 months and completely returned to the normal state at 6 months.Conclusion Omicron BA.1 breakthrough infection mainly evoked humoral immune memory in the original strain after vaccination and hardly produced neutralizing antibodies specific to Omicron BA.1. Neutralizing antibodies against the different strains declined rapidly and showed features similar to those of influenza. Thus, T-lymphocytes may play an important role in recovery.
引用
收藏
页码:614 / 624
页数:11
相关论文
共 50 条
  • [1] Effective Neutralizing Antibody Response Against SARS-CoV-2 Virus and Its Omicron BA.1 Variant in Fully Vaccinated Hematological Patients
    Danilo De Novellis
    Veronica Folliero
    Valentina Giudice
    Luca Pezzullo
    Giuseppina Sanna
    Raffaele Fontana
    Roberto Guariglia
    Carla Zannella
    Laura Mettivier
    Idalucia Ferrara
    Giovanni Boccia
    Maria Teresa Buonanno
    Maria Carmen Martorelli
    Serena Luponio
    Andrea Crudele
    Pasquale Pagliano
    Anna Maria Sessa
    Francesca Velino
    Maddalena Langella
    Aldo Manzin
    Massimiliano Galdiero
    Carmine Selleri
    Gianluigi Franci
    Bianca Serio
    Clinical and Experimental Medicine, 2023, 23 : 4943 - 4953
  • [2] Effective Neutralizing Antibody Response Against SARS-CoV-2 Virus and Its Omicron BA.1 Variant in Fully Vaccinated Hematological Patients
    De Novellis, Danilo
    Folliero, Veronica
    Giudice, Valentina
    Pezzullo, Luca
    Sanna, Giuseppina
    Fontana, Raffaele
    Guariglia, Roberto
    Zannella, Carla
    Mettivier, Laura
    Ferrara, Idalucia
    Boccia, Giovanni
    Buonanno, Maria Teresa
    Martorelli, Maria Carmen
    Luponio, Serena
    Crudele, Andrea
    Pagliano, Pasquale
    Sessa, Anna Maria
    Velino, Francesca
    Langella, Maddalena
    Manzin, Aldo
    Galdiero, Massimiliano
    Selleri, Carmine
    Franci, Gianluigi
    Serio, Bianca
    CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (08) : 4943 - 4953
  • [3] Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariants after mRNA SARS-CoV-2 vaccination in kidney transplant recipients
    Kawashiro, Keita
    Suzuki, Rigel
    Nogimori, Takuto
    Tsujino, Shuhei
    Iwahara, Naoya
    Hirose, Takayuki
    Okada, Kazufumi
    Yamamoto, Takuya
    Fukuhara, Takasuke
    Hotta, Kiyohiko
    Shinohara, Nobuo
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [4] Clinical Efficacy of the Neutralizing Antibody Therapy Sotrovimab in Patients with SARS-CoV-2 Omicron BA.1 and BA.2 Subvariant Infections
    Miyashita, Naoyuki
    Nakamori, Yasushi
    Ogata, Makoto
    Fukuda, Naoki
    Yamura, Akihisa
    Ishiura, Yoshihisa
    Ito, Tomoki
    VIRUSES-BASEL, 2023, 15 (06):
  • [5] Evasion of neutralizing antibody responses by the SARS-CoV-2 BA.2.75 variant
    Qu, Panke
    Evans, John P.
    Zheng, Yi-Min
    Carlin, Claire
    Saif, Linda J.
    Oltz, Eugene M.
    Xu, Kai
    Gumina, Richard J.
    Liu, Shan-Lu
    CELL HOST & MICROBE, 2022, 30 (09) : 1518 - +
  • [6] Correlation Analysis of Anti-SARS-CoV-2 RBD IgG and Neutralizing Antibody against SARS-CoV-2 Omicron Variants after Vaccination
    Takheaw, Nuchjira
    Liwsrisakun, Chalerm
    Chaiwong, Warawut
    Laopajon, Witida
    Pata, Supansa
    Inchai, Juthamas
    Duangjit, Pilaiporn
    Pothirat, Chaicharn
    Bumroongkit, Chaiwat
    Deesomchok, Athavudh
    Theerakittikul, Theerakorn
    Limsukon, Atikun
    Tajarernmuang, Pattraporn
    Niyatiwatchanchai, Nutchanok
    Trongtrakul, Konlawij
    Kasinrerk, Watchara
    DIAGNOSTICS, 2022, 12 (06)
  • [7] Strong Neutralizing Antibody Responses to SARS-CoV-2 Variants Following a Single Vaccine Dose in Subjects With Previous SARS-CoV-2 Infection
    Ekstrom, Nina
    Haveri, Anu
    Solastie, Anna
    Virta, Camilla
    Osterlund, Pamela
    Nohynek, Hanna
    Nieminen, Tuomo
    Ivaska, Lauri
    Tahtinen, Paula A.
    Lempainen, Johanna
    Jalkanen, Pinja
    Julkunen, Ilkka
    Palmu, Arto A.
    Melin, Merit
    OPEN FORUM INFECTIOUS DISEASES, 2022, 9 (12):
  • [8] Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone
    da Silva, Eveline Santos
    Kohnen, Michel
    Gilson, Georges
    Staub, Therese
    Arendt, Victor
    Hilger, Christiane
    Servais, Jean-Yves
    Charpentier, Emilie
    Domingues, Olivia
    Snoeck, Chantal J.
    Ollert, Markus
    Seguin-Devaux, Carole
    Perez-Bercoff, Danielle
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (14)
  • [9] The serological IgG and neutralizing antibody of SARS-CoV-2 omicron variant reinfection in Jiangsu Province, China
    Chu, Jinjin
    Dai, Qigang
    Dong, Chen
    Kong, Xiaoxiao
    Tian, Hua
    Li, Chuchu
    Peng, Jiefu
    Xu, Ke
    Ju, Hao
    Bao, Changjun
    Hu, Jianli
    Zhu, Liguo
    FRONTIERS IN PUBLIC HEALTH, 2024, 12
  • [10] Emergence and spread of the SARS-CoV-2 omicron (BA.1) variant across Africa: an observational study
    Fischer, Carlo
    Maponga, Tongai Gibson
    Yadouleton, Anges
    Abilio, Nuro
    Aboce, Emmanuel
    Adewumi, Praise
    Afonso, Pedro
    Akorli, Jewelna
    Andriamandimby, Soa Fy
    Anga, Latifa
    Ashong, Yvonne
    Beloufa, Mohamed Amine
    Bensalem, Aicha
    Birtles, Richard
    Boumba, Anicet Luc Magloire
    Bwanga, Freddie
    Chaponda, Mike
    Chibukira, Paradzai
    Chico, R. Matthew
    Chileshe, Justin
    Choga, Wonderful
    Chongwe, Gershom
    Cisse, Assana
    Cisse, Fatoumata
    D'Alessandro, Umberto
    de Lamballerie, Xavier
    de Morais, Joana F. M.
    Derrar, Fawzi
    Dia, Ndongo
    Diarra, Youssouf
    Doumbia, Lassina
    Drosten, Christian
    Dussart, Philippe
    Echodu, Richard
    Eloualid, Abdelmajid
    Faye, Ousmane
    Feldt, Torsten
    Fruehauf, Anna
    Gaseitsiwe, Simani
    Halatoko, Afiwa
    Iipumbu, Etuhole
    Ilouga, Pauliana-Vanessa
    Ismael, Nalia
    Jambou, Ronan
    Jarju, Sheikh
    Kamprad, Antje
    Katowa, Ben
    Kayiwa, John
    King'wara, Leonard
    Koita, Ousmane
    LANCET GLOBAL HEALTH, 2025, 13 (02): : E256 - E267